Royalty Report: Drugs, Delivery, Pharmaceuticals – Collection: 6973


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Delivery
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6973

License Grant
The Licensee entered into a License Agreement with the Licensor, a company incorporated in British Columbia, Canada, and controlled by two individuals related to the president of our Licensee, for the exclusive use of the Licensor's sublingual technology for drug delivery of the Licensee's products.
License Property
Patent appears in the heading “Method of Delivering Pharmaceutical Products Sublingually'
Sublingual refers to the pharmacological route of administration by which substances diffuse into the blood through tissues under the tongue which is predominantly a mucous gland primarily produces a thick mucinous fluid and lubricates the oral cavity which allows for swallowing, initiating digestion, buffering pH, and dental hygiene.
Field of Use
The Licensee is a development stage specialty pharmaceutical company engaged in developing proprietary platform technology that delivers drugs via the sublingual (under the tongue) route. We are also developing oral formulations of drugs which are intended to cause fewer stomach side effects than formulations of such drugs previously marketed by other pharmaceutical companies.

IPSCIO Record ID: 7576

License Grant
Canadian Licensor hereby grants to the Canadian Licensee, an exclusive worldwide, perpetual license under the Patents and the Licensed Know-How, with such exclusivity being limited to the right to and for the sole purpose the Licensed Application ('License').  The Oral Dissolving Technology is exclusively available to the Canadian Licensee through the License Agreement.
License Property
'Product' shall mean Sildenafil Citrate.

An orally disintegrating tablet or orodispersible tablet (ODT) is a drug dosage form available for a limited range of over-the-counter and prescription medications. ODTs differ from traditional tablets in that they are designed to be dissolved on the tongue rather than swallowed whole.

'Licensed Patents' shall mean Intellectual Property solely relating to the Product and US Patent Application 2007/01.90144 (Novel formulation for sublingual drug delivery and use thereof) and all corresponding know-how, patents, patent applications, continuation applications, continuation, etc.

Field of Use
'Field of Use' shall mean oral dissolving technology (sublingual) delivery of the Product.

The first product the Licensee will develop with this technology is sublingual sildenafil. This therapy is used for erectile disfuction.

The Licensee is to complete the required studies and regulatory tasks to commercialize products using the oral dissolving technology and is responsible for any all clinical trials related to the development of products using ODT technology.

IPSCIO Record ID: 1661

License Grant
The Company obtained exclusive United States rights to a U.S. patent relating to the sublingual delivery of sex steroids, in which the drug is absorbed into the bloodstream through the mucosal membrane under the tongue.
Field of Use
The rights granted relate to steroids.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.